TNNC1
MOLECULAR TARGETtroponin C1, slow skeletal and cardiac type
TNNC1 (troponin C1, slow skeletal and cardiac type) is targeted by 5 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting TNNC1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | fingolimod | 4.11 | 60 |
| 2 | hydroxyindoleacetic acid | 0.69 | 1 |
| 3 | Memantine AMANTADINE derivative that has some dopaminergic effects. It has been proposed as | 0.69 | 1 |
| 4 | Niridazole | 0.69 | 1 |
| 5 | Oxytetracycline | 0.69 | 1 |
About TNNC1 as a Drug Target
TNNC1 (troponin C1, slow skeletal and cardiac type) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 5 compounds with documented TNNC1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
TNNC1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.